Meike Vogler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meike Vogler has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Gerald M. Cohen
Department of Biochemistry University of Leicester Leicester UK
2 shared publications- Martin J. S. Dyer
The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, College of Life Sciences, University of Leicester, Leicester LE1 9HN, UK
2 shared publications - Andrew Owen
Centre of Excellence in Long-acting Therapeutics (CELT), Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
1 shared publication - David Dickens
Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
1 shared publication David Dinsdale
MRC Toxicology Unit University of Leicester Leicester UK
1 shared publication- Munir Pirmohamed
University of Liverpool Department of Pharmacology and Therapeutics
1 shared publication
Latest Publications
- Open Access
- 4 July 2013
- Published by Wiley in British Journal of Haematology
- Vol. 163 (1) , 139-142
ABT‐199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets
- 4 July 2013
- Published by Wiley in British Journal of Haematology
- Vol. 163 (1) , 139-142
Open AccessABT‐199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets
- 11 November 2011
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 19 (1) , 67-74
BCL2A1: the underdog in the BCL2 family
B-cell lymphoma 2 (BCL2) proteins are important cell death regulators, whose main function is to control the release of cytochrome c from mitochondria in the intrinsic apoptotic pathway. They comprise both pro- and anti-apoptotic proteins, which interact in various ways to induce or prevent pore formation in the outer mitochondrial membrane. Due to their central function in the apoptotic machinery, BCL2 proteins are often deregulated in cancer. To this end, many anti-apoptotic BCL2 proteins have been identified as important cellular oncogenes and attractive targets for anti-cancer therapy. In this review, the existing knowledge on B-cell lymphoma 2-related protein A1 (BCL2A1)/Bcl-2-related gene expressed in fetal liver (Bfl-1), one of the less extensively studied anti-apoptotic BCL2 proteins, is summarized. BCL2A1 is a highly regulated nuclear factor κB (NF-κB) target gene that exerts important pro-survival functions. In a physiological context, BCL2A1 is mainly expressed in the hematopoietic system, where it facilitates survival of selected leukocytes subsets and inflammation. However, BCL2A1 is overexpressed in a variety of cancer cells, including hematological malignancies and solid tumors, and may contribute to tumor progression. Therefore, the development of small molecule inhibitors of BCL2A1 may be a promising approach mainly to sensitize tumor cells for apoptosis and thus improve the efficiency of anti-cancer therapy.
- 11 November 2011
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 19 (1) , 67-74
BCL2A1: the underdog in the BCL2 family
B-cell lymphoma 2 (BCL2) proteins are important cell death regulators, whose main function is to control the release of cytochrome c from mitochondria in the intrinsic apoptotic pathway. They comprise both pro- and anti-apoptotic proteins, which interact in various ways to induce or prevent pore formation in the outer mitochondrial membrane. Due to their central function in the apoptotic machinery, BCL2 proteins are often deregulated in cancer. To this end, many anti-apoptotic BCL2 proteins have been identified as important cellular oncogenes and attractive targets for anti-cancer therapy. In this review, the existing knowledge on B-cell lymphoma 2-related protein A1 (BCL2A1)/Bcl-2-related gene expressed in fetal liver (Bfl-1), one of the less extensively studied anti-apoptotic BCL2 proteins, is summarized. BCL2A1 is a highly regulated nuclear factor κB (NF-κB) target gene that exerts important pro-survival functions. In a physiological context, BCL2A1 is mainly expressed in the hematopoietic system, where it facilitates survival of selected leukocytes subsets and inflammation. However, BCL2A1 is overexpressed in a variety of cancer cells, including hematological malignancies and solid tumors, and may contribute to tumor progression. Therefore, the development of small molecule inhibitors of BCL2A1 may be a promising approach mainly to sensitize tumor cells for apoptosis and thus improve the efficiency of anti-cancer therapy.
- 1 May 2011
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 408 (2) , 344-349
The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein
- 1 May 2011
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 408 (2) , 344-349
The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein